Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 11/20 | 0.59 |
| ▸ | CTSK | P43235 | 9/20 | 0.59 |
| ▸ | CTSB | P07858 | 3/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | BCL2 | P10415 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 3/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28572952 | 1.00 | CTSS (0.59) | CTSSCTSKCTSBCTSLPTPN1 | |
| SCHEMBL30866 | 1.00 | CTSS (0.59) | CTSSCTSKCTSBCTSLPTPN1 | |
| SCHEMBL45753 | 1.00 | CTSS (0.59) | CTSSCTSKCTSBCTSLPTPN1 | |
| SCHEMBL29373190 | 1.00 | CTSS (0.59) | CTSSCTSKCTSBCTSLPTPN1 | |
| SCHEMBL30867 | 1.00 | CTSS (0.59) | CTSSCTSKCTSBCTSLPTPN1 | |
| SCHEMBL18765 | 1.00 | CTSS (0.59) | CTSSCTSKCTSBCTSLPTPN1 | |
| SCHEMBL13566632 | 1.00 | CTSS (0.59) | CTSSCTSKCTSBCTSLPTPN1 | |
| SCHEMBL15415630 | 0.93 | ATM (0.57) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL2507124 | 0.93 | ATM (0.57) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL15415629 | 0.93 | ATM (0.57) | CTSSCTSKCTSBCTSLATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802887-B2 | Process for the preparation of intermediates useful for the manufacture NEP inhibitors | NOVARTIS AG (CH) | 2017-10-31 | — | — | US | claimed |
| EP-2609071-B1 | NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE OF NEP INHIBITORS | NOVARTIS AG (CH) | 2016-09-21 | — | — | EP | claimed |
| US-20150274650-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | HOOK DAVID (CH) | 2015-10-01 | — | — | US | claimed |
| US-9802887-B2 | Process for the preparation of intermediates useful for the manufacture NEP inhibitors | NOVARTIS AG (CH) | 2017-10-31 | — | — | US | disclosed |
| US-9802887-B2 | Process for the preparation of intermediates useful for the manufacture NEP inhibitors | NOVARTIS AG (CH) | 2017-10-31 | — | — | US | disclosed |
| EP-2609071-B1 | NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE OF NEP INHIBITORS | NOVARTIS AG (CH) | 2016-09-21 | — | — | EP | disclosed |
| US-20150274650-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | HOOK DAVID (CH) | 2015-10-01 | — | — | US | disclosed |
| US-9085529-B2 | Process for the preparation of intermediates useful for the manufacture NEP inhibitors | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| EP-2609071-A1 | NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | Novartis AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-20130158275-A1 | NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | NOVARTIS AG (CH) | 2013-06-20 | — | — | US | disclosed |
| WO-2012025502-A1 | NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | NOVARTIS AG (CH) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158275-A1 | NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | MME, DNPEP, REN | CTSS 528/4885CTSK 1306/4885CTSB 473/4885 |
| US-20150274650-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | MME, DNPEP, REN | CTSS 539/4885CTSK 1034/4885CTSB 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.